These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10963819)

  • 1. Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus.
    Wan Mohamad WB; Tun Fizi A; Ismail RB; Mafauzy M
    Diabetes Res Clin Pract; 2000 Aug; 49(2-3):93-9. PubMed ID: 10963819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance.
    Charpentier G; Fleury F; Dubroca I; Vaur L; Clerson P
    Diabetes Metab; 2005 Apr; 31(2):189-95. PubMed ID: 15959425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
    Seino Y; Rasmussen MF; Nishida T; Kaku K
    Curr Med Res Opin; 2010 May; 26(5):1013-22. PubMed ID: 20199137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
    Draeger KE; Wernicke-Panten K; Lomp HJ; Schüler E; Rosskamp R
    Horm Metab Res; 1996 Sep; 28(9):419-25. PubMed ID: 8911976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
    Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
    Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
    Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
    Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity.
    Kabadi UM; McCoy S; Birkenholz M; Kabadi M
    Diabet Med; 1995 Oct; 12(10):880-4. PubMed ID: 8846678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up.
    Alvarsson M; Sundkvist G; Lager I; Berntorp K; Fernqvist-Forbes E; Steen L; Orn T; Holberg MA; Kirksaether N; Grill V
    Diabetes Obes Metab; 2008 May; 10(5):421-9. PubMed ID: 17394534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
    Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
    Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M; Swatko A; Hilberg C; Shestakova M
    Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different insulin regimens in elderly patients with NIDDM.
    Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
    Herz M; Sun B; Milicevic Z; Erickson P; Fövènyi J; Grzywa M; Pelikanova T
    Clin Ther; 2002 Jan; 24(1):73-86. PubMed ID: 11833837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients.
    Ročić B; Znaor A; Ročić P; Weber D; Vučić Lovrenčić M
    Wien Med Wochenschr; 2011 Nov; 161(21-22):519-23. PubMed ID: 21792527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J; Spengler M
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
    Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H
    Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial.
    Brunetti P; Pagano G; Turco C; Gori M; Perriello G;
    Diabetes Nutr Metab; 2004 Dec; 17(6):350-7. PubMed ID: 15887629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide versus glibenclamide in patients with diabetes.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin.
    Marre M; Howlett H; Lehert P; Allavoine T
    Diabet Med; 2002 Aug; 19(8):673-80. PubMed ID: 12147149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.